From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
S-22153 is a potent melatonin receptor antagonist with EC50 values of 19 nM, 4.6 nM for hMT1 and hMT2 melatonin receptor, respectively. S-22153 has Ki values of 8.6 nM (CHOcells) and 16.3 nM (HEK cells) for hMT1, and 6.0 nM (CHOcells) and 8.2 nM (HEK cells) for hMT2. S-22153 is a specific ligand of MT1 and MT2 melatonin receptors subtypes .
Arachidonylcyclopropylamide (ACPA) is a potent and selective CB1 receptors agonist. Arachidonylcyclopropylamide inhibits forskolin-stimulated cAMP production in CHOcells transfected with human cannabinoid CB1 receptors (IC50=2 nM) .
SR 142948 is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHOcells, HT-29 cells, and adult rat brain, respectively. SR 142948 antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 shows blood-brain permeability and can be used in study of psychiatric disorders .
AB-MECA is a high affinity A3 adenosine receptor agonist with a binding Ki of 430.5 nM for human A3 receptors in CHOcells. AB-MECA can enhance plasma histamine level .
BAN ORL 24 is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 has antagonistic effect for nociceptin (NOP) receptor with KI value of 0.24 nM in CHOcell. BAN ORL 24 can be used for the research of cancer and analgesic .
BCTP is a TRPV1 antagonist. BCTP activated at low pH showed functional antagonist activity against human TRPV1 in CHOcells (IC50=18 nM). BCTP can be used in the study of chronic pain .
3-Hydroxy darifenacin is a metabolite of Darifenacin (HY-A0033). 3-Hydroxy darifenacin is an antagonist of M1-5 muscarinic receptors with Kis values of 17.78, 79.43, 2.24, 36.31 and 6.17 nM, respectively in CHOcells .
TRPV1 antagonist 9 (compound 13c) is an orally active transient receptor potential vanilloid 1 (TRPV1) channel antagonist. TRPV1 antagonist 9 blocks Ca 2+ uptake by CHOcells expressing TRPV1 receptors with IC50 values are 0.6 and 0.8 nM for Capsaicin (HY-10448) and acid-induced Ca 2+ uptake, respectively. TRPV1 antagonist 9 blocks Capsaicin (HY-10448)-induced flinch response and causes hyperthermia in rats .
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHOcells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHOcells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .
L-748328 is a potent and selective human β3-adrenergic receptor antagonist. L-748328 has a Ki of 3.7 nM against human cloned β3-AR expressed in Chinese hamster ovary (CHO) cells. In addition, L-748328 inhibits the lipolytic response induced by the β3-AR agonist L-742791 in isolated non-human primate adipocytes .
A1899 is a potent and highly selective blocker of the K2P channel TASK-1. A1899 has IC50 values of 35.1 nM and 7 nM for TASK-1 channels expressed in oocytes and CHOcells, respectively. A1899 is also an IKur blocker that can be used for the research of cardiovascular diseases .
Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac potassium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac diethylamine induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
Diclofenac (Standard) is the analytical standard of Diclofenac. This product is intended for research and analytical applications. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
Diclofenac (potassium) (Standard) is the analytical standard of Diclofenac (potassium). This product is intended for research and analytical applications. Diclofenac potassium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac potassium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
Diclofenac (diethylamine) (Standard) is the analytical standard of Diclofenac (diethylamine). This product is intended for research and analytical applications. Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac diethylamine induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHOcells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
Ac- IETD- CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac- IETD- CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac- IETD- CHO also inhibits cytotoxic T lymphocytes induced cell death .
AH22921 is an EP4 prostaglandin receptor antagonist with the activity of antagonizing the activation of adenylate cyclase by prostaglandins in CHOcells. AH22921 can shift the PGE2 concentration-response curve to the right in CHOcells. It is a non-competitive antagonist that is selective for EP4 receptors and has an antagonistic effect on EP4 receptors in CHOcells, but does not affect the PGE2 concentration-response curve in NPE cells containing EP2 receptors.
CB-25 is a ligand of CB1cannabinoid receptors, acting as a partial agonist. CB-25 enhances Forskolin (HY-15371)-induced cAMP formation in cancer cells but not hCB1-CHOcells .
SP3CHO is an active metabolite generated by the metabolism of SP3N in cell culture by the action of amine oxidase. SP3CHO can induce polyubiquitination of specific proteins by recruiting the SCFFBXO22 E3 ligase complex. SP3CHO can be used in cancer therapy research .
Ac-AAVALLPAVLLALLAP-LEHD-CHO is an inhibitor of caspases 4, 5 and 9. Ac-AAVALLPAVLLALLAP-LEHD-CHO shows protective effects upon Neocarzinostatin (HY-111183)-treated MCF-7 cells .
PSB-1901 is a potent A2B adenosine receptor (A2BAR) antagonist with Kis of 0.0835 nM and 0.131 nM for human and mouse A2BARs respectively. PSB-1901 can be used for the research of cancer .
Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
Turoctocog alfa is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa can be used for researching haemophilia A .
NPFF1-R antagonist 1 (compound 8b), a piperidine analogue, is a potent neuropeptide FF (NPFF) receptor antagonist. NPFF1-R antagonist 1 is 15-fold selective for the NPFF1-R subtype, with Ki values of 211 nM and 3270 nM for NPFF1-R and NPFF2-R, respectively .
Hyodeoxycholic acid sodium is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells .
Talnetant (SB 223412) is a selective, competitive, brain-permeable NK3 receptor antagonist with a Ki of 1.4 nM in hNK-3-CHOcells. Talnetant is 100-fold more selective for hNK-3 relative to the hNK-2 receptor and has no affinity for hNK-1. Talnetant can be used in schizophrenia-related studies .
Talnetant (SB 223412) hydrochloride is a selective, competitive, brain-permeable NK3 receptor antagonist with a Ki of 1.4 nM in hNK-3-CHOcells. Talnetant hydrochloride is 100-fold more selective for hNK-3 relative to the hNK-2 receptor and has no affinity for hNK-1. Talnetant hydrochloride can be used in schizophrenia-related studies .
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHOcells.
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
3-Aminobenzamide (PARP-IN-1) is a potent inhibitor of PARP with IC50 of appr 50 nM in CHOcells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.
SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHOcells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders .
CFMTI inhibits L-glutamate-induced intracellular Ca 2+ mobilization in CHOcells expressing human and rat mGluR1a, with IC50s of 2.6 and 2.3 nM, respectively .
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells .
AM-4668 is a GPR40 agonist for type 2 diabetes. EC50s of 3.6 nM and 36 nM for GPR40 in A9 cells (GPR40 IP3 assay) and CHOcells (GPR40 aequorin assay), respectively .
BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC50 of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a Ki value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease .
(E)-PHCCC is a positive allosteric modulator (PAM) for mGluR4, that enhances the activity of the receptor's endogenous ligand (glutamate), and exhibits activity in the calcium mobilization assay in CHOcells with an EC50 of 3.2 μM .
(Rac)-MGV354 is the racemate of MGV354. MGV354 is a soluble guanylate cyclase (sGC) activator with EC50s of <0.5 nM, and 5 nM in CHO and GTM-3 E cells, respectively .
Rezuforimod is the agonist for N-formyl peptide receptor like-1 receptor (FPRL-1) with an EC50 of 0.88 nM in CHO-Ga16 cell. Rezuforimod exhibits anti-inflammatory activity .
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Mianserin-d3 is the deuterium labeled Mianserin (HY-B0188). Mianserin? is a Histamine 1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant .
Hyodeoxycholic acid-d5 is the deuterium labeled Hyodeoxycholic acid. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish .
Netupitant (CID-6451149) is a highly potent, selective and orally active neurokinin-1 (NK1) receptor antagonist with a Ki of 0.95 nM for hNK1 in CHOcells. Netupitant has antiemetic affect .
AG 99 (Tyrphostin 46), a tyrphostin derivative, is a tyrosine kinase inhibitor that increases sister chromatid exchange frequency in transformed CHO-K1 and primary CHE cells. AG 99 is promising for research of proliferative diseases .
AM095 is a selective LPA1 receptor antagonist. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHOcells is 0.025 and 0.023 μM, respectively.
Hyodeoxycholic acid (Standard) is the analytical standard of Hyodeoxycholic acid. This product is intended for research and analytical applications. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
Anti-MUC17 Antibody is a human antibody expressed in CHOcells, targeting MUC17. Anti-MUC17 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Hyodeoxycholic acid (Standard) is the analytical standard of Hyodeoxycholic acid. This product is intended for research and analytical applications. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHOcells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHOcells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
GR 159897 is a highly potent, selective, competitive, brain-penetrated non-peptide neurokinin 2 (NK2) receptor antagonist. GR 159897 has little or no affinity for NK1 and NK3 receptors. GR 159897 inhibits binding of [ 3H]GR100679 to human NK2(hNK2)-CHO cells and rat colon membranes with pKis of 9.51 and 10, respectively. Antagonizes bronchoconstriction. Anxiolytic-like and anti-tumor effects .
Anti-Clathrin Heavy Chain Antibody is a human antibody expressed in CHOcells, targeting Clathrin Heavy Chain. Anti-Clathrin Heavy Chain Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TrkB/NTRK2 Antibody is a human antibody expressed in CHOcells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-EMMPRIN/CD147 Antibody is a human antibody expressed in CHOcells, targeting Basigin. Anti-EMMPRIN/CD147 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Spike-RBD mAb is a CHOcell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
Anti-IL-25 Antibody is a human antibody expressed in CHOcells, targeting IL-25. Anti-IL-25 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHOcell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats .
Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHOcell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats .
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHOcells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHOcell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
CAY10669 (compound 6d) is an anacardic acid (HY-N2020) derivative that inhibits histone acetyltransferase PCAF with an IC50 of 662 μM . CAY10669 enhances the SAHA-induced acetylation in HEPG2 cells, exhibits cytotoxicity in zebrafish embryo, promotes transgene expression in CHO-K1 cells .
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin TSLP. The expression system of Ecleralimab is usually CHO (Chinese Hamster Ovary) cells .
SKF89976A is a selective GABA transporter (GAT-1) inhibitor with IC50s of 0.28 μM, 137.34 μM and 202.8 μM for GAT-1, GAT-2 and GAT-3 in CHOcells, respectively.
SKF89976A hydrochloride is a selective GABA transporter (GAT-1) inhibitor with IC50s of 0.28 μM, 137.34 μM and 202.8 μM for GAT-1, GAT-2 and GAT-3 in CHOcells, respectively.
[DPro10] Dynorphin A (1-11), porcine, a N-Alkylated derivative, is a potent κ-opioid receptor agonist with a Ki value of 0.13 nM. [DPro10] Dynorphin A (1-11), porcine has analgesic property .
M1145 TFA, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 TFA shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 TFA has an additive effect on the signal transduction of galanin .
M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 has an additive effect on the signal transduction of galanin .
Anti-EFNA4 Antibody (PF-06647263 antibody) is a human antibody expressed in CHOcells, targeting EFNA4. Anti-EFNA4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
CGS 15943 is an orally bioavailable non-xanthine Adenosine Receptor antagonist. Its Ki for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM in transfected CHOcells, respectively. .
Lanicemine (AZD6765) dihydrochloride is a low-trapping NMDA channel blocker (Ki of 0.56-2.1?μM for NMDA receptor; IC50s of 4-7?μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
Indomethacin-d4 is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHOcells[1]. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes[2].
des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC50 of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC50=1.18±0.2 μM) of Nav1.5 expressed in Chinese hamster ovary (CHO-K1) cells .
AZ12672857 is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM) .
Indomethacin-d4 Methyl Ester is the deuterium labeled Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHOcells[1]. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes[2].
des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
L-796,778 is an agonist of the hsst3 receptor. In CHO-K1 cells expressing the hsst3 receptor, L-796,778 is a partial agonist that inhibits forskolin (HY-15371)-stimulated cAMP production with an IC50 value of 18 nM .
AC-42 is a poent M1 muscarinic selective allosteric agonist with EC50s of 805 nM and 220 nM for human wild-type and Y381A mutated M1 receptors, respectively. AC-42 stimulates the IP-accumulation and calcium mobilization in CHOcells .
SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHOcells expressing human B1 receptor, respectively.
(Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
Netupitant (Standard) is the analytical standard of Netupitant. This product is intended for research and analytical applications. Netupitant (CID-6451149) is a highly potent, selective and orally active neurokinin-1 (NK1) receptor antagonist with a Ki of 0.95 nM for hNK1 in CHOcells. Netupitant has antiemetic affect .
V1a/V2 antagonist 1 (Compound 18j) is an orally active dual V1a and V2 receptor antagonist with high binding affinity for both receptors (Ki: 0.13 nM for hV1a, 0.53 nM for hV2 and 0.5 nM for mV1a; IC50: 2.2 nM for hV1a). V1a/V2 antagonist 1 inhibits Oxytocin (HY-17571)-induced scratching behavior in mice .
Pro8-Oxytocin is a a modified oxytocin (OXT) ligand. Pro8-Oxytocin produces more potent and efficacious responses at primate OXTR and stronger behavioral effects than the consensus mammalian OXT ligand (Leu8-Oxytocin). Pro8-Oxytocin produce a less efficacious response than Vasopressin (HY-B1811) (AVP) at human AVPR1a and higher efficacious response than AVP at marmoset AVPR1a .
5-HT7R antagonist 3 (Compound 6.4) is a selective 5-HT7R antagonist (Ki: 8 nM), with Ki of 511 nM (D2), 8930 nM (5-HT1A) and 5786 nM (5-HT2A), respectively. 5-HT7R antagonist 3 possesses antidepressant and anxiolytic effects in mice .
Aldicarb sulfoxide-d3 is the deuterium labled Aldicarb sulfoxide (HY-124104). Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish .
BAN ORL 24 free base is a nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP) antagonist. BAN ORL 24 free base has antagonistic effect for nociceptin (NOP) receptor with KI value of 0.24 nM in CHOcell. BAN ORL 24 free base can be used for the research of cancer and analgesic .
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHOcells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
hCYP3A4-IN-1 (compound C6) is a potent, orally active hCYP3A4 inhibitor. hCYP3A4-IN-1 shows the IC50 values of 43.93 nM and 153.00 nM against hCYP3A4 in human liver microsomes (HLMs) and CHO-3A4 stably transfected cell line, respectively. hCYP3A4-IN-1 potently inhibits CYP3A4-catalyzed N-ethyl-1,8-naphthalimide (NEN) hydroxylation in a competitive manner (Ki = 30.00 nM) .
Diclofenac-d4 (sodium) is the deuterium labeled Diclofenac sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3].
Diclofenac-d4 is the deuterium labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3].
(R)-Lanicemine ((R)-AZD6765) is the less active R-enantiomer of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
2,6-Dichlorodiphenylamine is an analogue of Diclofenac Sodium (HY-15037) and has anti-Candida albicans activity. Diclofenac Sodium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells.
Indomethacin farnesil is an orally active proagent of Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHOcells. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes .
RNA polymerase II-IN-2 (compound 20iii) is a potent RNA polymerase II (Pol II) inhibitor with Ki value of 9.5 nM. RNA polymerase II-IN-2 has cytotoxicity against cancer cells, and exhibits 2 and 5 fold toxicity than α-amanitin against CHO and HEK293 .
FR104 is a humanized antibody expressed in CHOcells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively .
CMKLR1 antagonist 1 (compound S-26d) is a potent and orally active chemokine-like receptor 1 (CMKLR1) antagonist, with a pIC50 value of 7.44 in hCMKLR1-transfected CHOcells. CMKLR1 antagonist 1 can be used for psoriasis and metabolic diseases research .
Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) is a human antibody expressed in CHOcells, targeting CDH6. Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Diclofenac- 13C6 (sodium heminonahydrate) is the 13C-labeled Diclofenac Sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3].
Diclofenac- 13C6 (Sodium) is the 13C6 labeled Diclofenac (Sodium). Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.
Diclofenac- 13C6 is the 13C6 labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.
The Anti-oxLDL Antibody is a humanized antibody expressed in CHOcells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CDH17/Cadherin-17 Antibody (10C12) is a human antibody expressed in CHOcells, targeting CDH17. Anti-CDH17/Cadherin-17 Antibody (10C12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
PTAC oxalate is a selective muscarinic receptor ligand. PTAC oxalate is an partial agonist of M2 and M4 but antagonist of M1, M3, and M5 (Ki values of 0.2-2.8 nM for hM1-5 in CHOcells). PTAC oxalate alleviates the mechanical allodynia on the neuropathic pain and has antidepression effects .
Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca 2+ influx in hGluA1i CHOcells (EC50 = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .
Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively .
Anti-HGFA Antibody is a humanized antibody expressed in CHOcells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Senlizumab is a humanized antibody expressed in CHOcells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Antimycobacterial agent-2 (compound 58) is a potent antimycobacterial agent. Antimycobacterial agent-2 shows anti-mycobacterial activities with an MIC99 of 0.8 µM for Mycobacterium tuberculosis (M.tb) H37Rv. Antimycobacterial agent-2 shows cytotoxic activities with an IC50 of48.1 µM for CHOcells .
LPLRF-NH2 is a member of RFamide peptide with anorexigenic effect. LPLRF-NH2 increases arterial blood pressure and modulates the electrical activity of brainstem neurons .
PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain .
VGX-100 is a humanized antibody expressed in CHOcells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MB-311 is a humanized antibody expressed in CHOcells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPBG Antibody is a humanized antibody expressed in CHOcells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AC-42 hydrochloride is the hydrochloride salt form of AC-42 (HY-118806). AC-42 hydrochloride is an allosteric agonist for muscarinic M1 receptor with EC50s of 805 nM and 220 nM for human wild-type and Y381A mutated M1 receptors, respectively. AC-42 hydrochloride stimulates the inositol phosphate (IP)-accumulation and calcium mobilization in CHOcells .
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
Anti-LAP Antibody is a humanized antibody expressed in CHOcells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-vWF Antibody is a humanized antibody expressed in CHOcells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .
Topoisomerase IIα-IN-9 (NSC85582) is a bisphenol compound that has a moderate inhibitory effect on DNA topoisomerase Topoisomerase II (IC50: 571 μM). Topoisomerase IIα-IN-9 also exhibits a certain cell growth inhibitory effect, with IC50s of 117 μM and 218 μM for K562 and CHO, respectively .
Anti-TSLP Antibody is a human-derived antibody expressed in CHOcells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
KRN-330 is a humanized antibody expressed in CHOcells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLEC7A Antibody is a humanized antibody expressed in CHOcells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-MICB Antibody is a humanized antibody expressed in CHOcells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
SAIT-301 is a humanized antibody expressed in CHOcells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MRS-1191 is a potent and selective A3 adenosine receptor antagonist with a KB value of 92 nM, a Ki value of 31.4 nM for human A3 receptor and an IC50 of 120 nM for CHOcells . MRS-1191 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Diclofenac (Sodium) (Standard) is the analytical standard of Diclofenac (Sodium). This product is intended for research and analytical applications. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
FIPI is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .
Salmeterol-d3 is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].
VLST-002 is a humanized antibody expressed in CHOcells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
(±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a Ki of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHOcells expressing ORL1 with an IC50 value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ .
5HT2A antagonist 2 is an orally active, selective antagonist for 5HT2A with IC50 of 14 nM. 5-HT2A antagonist 2 exhibits good chemical, hepatocyte, and plasma stability, without significant cytotoxicity in cell lines VERO, HFL-1, L929, NIH3T3, CHO-K1 .
BT-063 is a humanized antibody expressed in CHOcells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
IMA-026 is a humanized antibody expressed in CHOcells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0701 is a humanized antibody expressed in CHOcells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
LE 300 is a potent and selective dopamine D1-like receptor antagonist with Kis of 1.9 nM and 7.5 nM in CHOcell membranes expressing human dopamine D1 and D5 receptors, respectively. LE 300 is an antagonist of the 5-HT2A receptor with a pA2 of 8.32 in a rat tail artery assay .
R707 is a human antibody expressed in CHOcells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
STX-100 is a humanized antibody expressed in CHOcells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
HuGAL-F2 is a human-derived antibody expressed in CHOcells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
[D-Trp8]-γ-MSH is a potent and selective agonist of melanocortin 3 (MC3) receptor, with IC50s of 6.7 nM, 600 nM and 340 nM for hMC3, hMC4 and hMC5, respectively in CHOcells. [D-Trp8]-γ-MSH could provide protection against multiple inflammatory disorders such as rheumatoid arthritis and colitis .
VB1-050 is a human antibody expressed in CHOcells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Salmeterol-d5 is a deuterated labeled Salmeterol . Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively .
DEDN6526A (RG-7636) is a humanized antibody expressed in CHOcells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHOcells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively .
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHOcells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD19 Antibody is a humanized antibody expressed in CHOcells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-STOP1 Antibody is a human antibody expressed in CHOcells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
[D-Trp8]-γ-MSH TFA is a potent and selective agonist of melanocortin 3 (MC3) receptor, with IC50s of 6.7 nM, 600 nM and 340 nM for hMC3, hMC4 and hMC5, respectively in CHOcells. [D-Trp8]-γ-MSH TFA could provide protection against multiple inflammatory disorders such as rheumatoid arthritis and colitis .
Anti-CXCL9 Antibody is a humanized antibody expressed in CHOcells, targeting CXCL9. The Anti-CXCL9 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXCL9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GAD65 Antibody is a humanized antibody expressed in CHOcells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Glucagon receptor antagonist-7 (Compound 1) is an antagonist for hGCGR, that inhibits the binding of 125I-labeled glucagon to the human glucagon receptor (hGCGR) with IC50 of 181 nM. Glucagon receptor antagonist-7 activates glucagon-stimulated adenylyl cyclase with a KDB of 81 nM in CHOcell. Glucagon receptor antagonist-7 inhibits glucagon-mediated glycogenolysis in human hepatocytes, and lowers blood glucose levels .
Anti-Orai1 Antibody is a humanized antibody expressed in CHOcells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHOcells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
AMG-628 is an orally active inhibitor for TRPV1, that inhibits Capsaicin (HY-10448) or acid (pH 5)-induced Ca 2+ influx into TRPV1- expressing CHOcell with IC50 of 4.9 and 3.1 nM. AMG-628 exhibits analgesic activity in Capsaicin (HY-10448)-induced rat model, and exhibits a half-life of 2.4 h in rats .
Cirazoline hydrochloride (LD 3098 hydrochloride) is a potent competitive full?α1A-adrenergic receptor (α1A-AR) agonist (Ki=120 nM) and only a partial agonist at α1B-AR (Ki= 960 nM) and α1D-AR (Ki=660 nM) .
SB-334867 (SB 334867A) is an excellent,selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
Fenarimol (EL 222) is a potent and orally active fungicide. Fenarimol also is a androgen receptor inhibitor with an IC50 value of 19 µM. Fenarimol decreases the mRNA expression of PBP C3, ODC, IGF-1 .
SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
VIB-9600 is a humanized antibody expressed in CHOcells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TGFb1 Antibody is a humanized antibody expressed in CHOcells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHOcells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Salmeterol-d3 (xinafoate) is the deuterium labeled Salmeterol xinafoate. Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].
Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHOcells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively .
Anti-PACAP38 Antibody is a human antibody expressed in CHOcells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Salmeterol- 13C6 (xinafoate) is the 13C6 labeled Salmeterol (xinafoate). Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHOcells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
RG-7212 (RO5458640) is a human-derived antibody expressed in CHOcells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
OS-2966 is a humanized antibody expressed in CHOcells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHOcells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Salmeterol (xinafoate) (Standard) is the analytical standard of Salmeterol (xinafoate). This product is intended for research and analytical applications. Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively .
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHOcells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
PDDHV is a calcium absorption inducer and may achieve 45Ca 2+ influx by stimulating vanillic acid receptor VR1. PDDHV induces 45Ca 2+ uptake (EC50: 70 nM) in rat dorsal root ganglion neurons (expressing native vanilloid receptors) and calcium mobilization (EC50: 125 nM) in VR1-transfected CHOcells. PDDHV also inhibits [3H]-resiniferatoxin (RTX) binding to the dorsal root ganglion membrane in rats .
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHOcells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DSG3 Antibody is a humanized antibody expressed in CHOcells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MGS0039 is a type II group mGluR antagonist. MGS0039 has a high affinity for mGluR2 and mGluR3, with Ki values of 2.2 nM and 4.5 nM, respectively. MGS0039 can attenuate the inhibitory effect of glutamate-induced cyclic AMP formation triggered by Forskolin (HY-15371) in CHOcells expressing mGluR2/mGluR3. MGS0039 shows antidepressant-like activity in rats .
AMG-108 is a humanized antibody expressed in CHOcells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
2,6-Dichlorodiphenylamine (Standard) is the analytical standard of 2,6-Dichlorodiphenylamine. This product is intended for research and analytical applications. 2,6-Dichlorodiphenylamine is an analogue of Diclofenac Sodium (HY-15037) and has anti-Candida albicans activity. Diclofenac Sodium is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells.
ABX-IL8 is a human-derived antibody expressed in CHOcells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
J-113397 is the first potent and selective nonpeptidyl ORL1 receptor antagonist (Ki: cloned human ORL1=1.8 nM) without any agonistic effects on other opioid receptors .
RG-15 is the orally active antagonist for dopamine receptor that exhibits goof affinity to human D2 receptor and human D3 receptor with pKi of 8.23 and 10.49. RG-15 inhibits dopamine-stimulated [ 35S]GTPγS binding with IC50 of 21.2 nM (rat striatal membranes), 36.7 nM (mouse A9 cells expressing human D2L receptors) and 7.2 nM (CHOcells expressing human D3 receptors). RG-15 increases the turnover and biosynthesis of dopamine in mouse striatum and olfactory bulb, exhibiting antipsychotic activity .
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHOcells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHOcells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHOcells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
(S)-AMG-628 (Compound 16q) is the S-isomer of AMG-628 (HY-123374). (S)-AMG-628 is the orally active antagonist for TRPV1, that inhibits the Capsaicin (HY-10448)- and acid-induced Ca 2+-influx with IC50 of 7 nM and 5 nM in CHOcell. (S)-AMG-628 ameliorates Capsaicin-induced rats flinching, and reverses the thermal hypersensitivity in CFA-(HY-153808) induced inflammatory pain models .
Leoidin is an OATP1B1 and OATP1B3 inhibitor with Ki values of 0.08 and 1.84 µM, respectively. Leoidin inhibits sodium fluorescein uptake in CHOcells expressing the human OATP1B1 and OATP1B3. Leoidin is an antibacterial agent against both Gram-positive and Gram-negative pathogens. Leoidin inhibits phenylalanyl-tRNA synthetase (PheRS) (IC50= 42 µM) and inhibits protein synthesis in bacterial. Leoidin can be isolated from L. gangaleoides .
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHOcells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ACVR2B Antibody is a human antibody expressed in CHOcells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
Anti-ADAM9 Antibody (MGA021) (IMGC-936 antibody) is a humanized antibody expressed in CHOcells that targets ADAM9. Anti-ADAM9 Antibody (MGA021) is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 147.62 kDa. The isotype control for Anti-ADAM9 Antibody (MGA021) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
AQ-RA 721 is a muscarinic receptor antagonist with differential affinity for the m4 and M2 sites, which can be used to characterize muscarinic receptor subtypes. Other muscarinic receptor antagonists have differential affinity for the M1 (rat cerebral cortex), M2 (rat heart), M3 (rat submandibular gland), m4 (receptor expressed in Chinese hamster ovary cells transfected with CHO), and guinea pig uterine smooth muscle at the muscarinic binding site .
C2 L-threo Ceramide (d18:1/2:0) (L-threo Cer(d18:1/2:0); L-threo Ceramide (d18:1/2:0)) is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. It stimulates cholesterol efflux in CHOcells expressing the human ABCA1 receptor when used at a concentration of 10 μM, however, this efflux is 50% less than that stimulated by C2 ceramide. C2 L-threo Ceramide inhibits IL-4 production by 17% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. It also induces cell cycle arrest in the G0/G1 phase and a 7-fold increase in sphingosine accumulation as well as inhibits growth of HL-60 leukemia cells.
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHOcells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Antimalarial agent 41 (Compound 17) exhibits antimalarial activity, which inhibits Plasmodium falciparum with an IC50 of 40 nM (NF54 strain) and 76 nM (K1 strain). Antimalarial agent 41 is an inhibitor for P. falciparum phosphatidylinositol-4-kinase β (Pf PI4K) and hERG channel, with an IC50 of 53 nM and 3 μM. Antimalarial agent 41 exhibits cytotoxicity to CHOcells with an IC50 of 34 μM. Antimalarial agent 41 ameliorates the malaria infection and exhibits good pharmacokinetic characters in mouse models .
MCH (human, mouse, rat) is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHOcell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
ARC 239 dihydrochloride is a selective α2B/2C adrenoceptor antagonist (pKd values are 5.95, 7.41 and 7.56 at α2A, α2B, and α2C receptors respectively). ARC 239 dihydrochloride binds to CHOcell membranes expressing human recombinant a2A-, a2B- or a2C-adrenoceptor subtypes with pKis of 5.6, 8.4, and 7.08, respectively .
RG100204 is an orally active AQP9 inhibitor with anti-inflammatory activity. RG100204 can alleviate sepsis-induced cardiac dysfunction (both systolic and diastolic), improve renal dysfunction, and reduce the elevation of LDH, a marker of cellular injury .
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHOcells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHOcells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFSF2/TNFa Antibody (hMAK195) is a human antibody expressed in CHOcells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHOcell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHOcells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Osemitamab (FUT8-KO) is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study. Osemitamab (FUT8-KO) antibody is expressed in FUT8-knockout CHOcells. Osemitamab (FUT8-KO) possesses a more potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) than Osemitamab .
Edonentan (BMS 207940) is an antagonist for endothelin receptor (ETA receptor), with a Ki of 10 pM. Edonentan is metabolic stable, exhibits good pharmakokinetic characters in rats. Edonentan regulates the endothelin system, blocks the big Endothelin-induced pressor response in rats model .
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHOcells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CEACAM1/CD66a Antibody is a human antibody expressed in CHOcells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHOcells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHOcells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHOcells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CTLA-4/CD152 Antibody is a humanized antibody expressed in CHOcells that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHOcells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHOcells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
DA-6886 is a 5-Hydroxytryptamine receptor 4 (5-HT4) agonist. DA-6886 induces relaxation of the rat oesophagus preparation in a 5-HT4 receptor antagonist-sensitive manner. The evaluation of DA-6886 in CHOcells expressing hERG channels reveals that it inhibits hERG channel current with an pIC50 value of 4.3, indicating that the compound is 1000-fold more selective for the 5-HT4 receptor over hERG channels. DA-6886 can be used in the study of constipated irritable bowel syndrome .
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC50 value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .
The Anti-LY75/CD205 Antibody (MEN1309) is a human antibody expressed in CHOcells, targeting LY75/CD205/DEC-205. The Anti-LY75/CD205 Antibody (MEN1309) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.36 kDa. For the isotype control of Anti-LY75/CD205 Antibody (MEN1309), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2?binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHOcells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHOcells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .
SB 206553 is a 5-HT2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT2A), 7.7 nM (5-HT2B) and 7.8 nM (5-HT2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders .
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHOcells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cellapoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease .
S 32212 hydrochloride is an inverse agonist of 5-HT receptors5-HT2(CINI) and 5-HT2(CVSV) (Kis=6.6, 8.9 nM) and an antagonist of 5-HT2A and α2β-adrenergic receptors (Ki=5.8, 5.8 nM). S 32212 hydrochloride can reduce the binding of GTPγS to Gαq, and reduce the activity of phospholipase C (PLC) in HEK293 cells expressing 5-HT2(CINI) receptor and CHOcells expressing 5-HT2(CVSV) receptor (EC50=38 and 18.6 nM, respectively). S 32212 hydrochloride (2.5 mg/kg) reduces 5-HT receptor agonist-induced head twitches and penile erections in mice and rats. S 32212 hydrochloride (10, 40 mg/kg) reduces immobility time in the forced swim test and marble burying behavior in mice and rats, exerting antidepressant and anxiolytic activities.
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHOcells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NRX-0492 is an orally active PROTAC-class BTK degrader. NRX-0492 catalyzes BTK ubiquitination and proteasome degradation (DC50 ≤ 0.2 nM, DC90 ≤ 0.5 nM) . NRX-0492 inhibits B cell receptor (BCR) mediated signaling, transcription programs, and chemokine secretion. NRX-0492 can bind non-covalently to the BTK binding domain and cereblon, which is an adapter protein in the E3 ubiquitin ligase complex . NRX-0492 consists of a target protein ligand (red part) BTK-IN-40 (HY-170324), an E3 ligase ligand (blue part) Thalidomide 5-fluoride (HY-W087383), and a PROTAC linker (black part) (3R)-3-Pyrrolidinemethanol (HY-60263). E3 ubiquitin ligase and linker can form Thalidomide 5-pyrrolidine-CHO (HY-49372A); the active control for the target protein ligand is BTK ligand 12 (HY-49421).
SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd=5.03 nM), exhibits 100-fold selectivity for OX1 over OX2 receptors with IC50 values of 3.76 nM and 531 nM, respectively .
Hyodeoxycholic acid sodium is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells .
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHOcells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHOcells (Kd=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ 35S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .
Ac- IETD- CHO is a potent, reversible inhibitor of granzyme B and caspase-8. Ac- IETD- CHO inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac- IETD- CHO also inhibits cytotoxic T lymphocytes induced cell death .
Ac-AAVALLPAVLLALLAP-LEHD-CHO is an inhibitor of caspases 4, 5 and 9. Ac-AAVALLPAVLLALLAP-LEHD-CHO shows protective effects upon Neocarzinostatin (HY-111183)-treated MCF-7 cells .
[DPro10] Dynorphin A (1-11), porcine, a N-Alkylated derivative, is a potent κ-opioid receptor agonist with a Ki value of 0.13 nM. [DPro10] Dynorphin A (1-11), porcine has analgesic property .
M1145 TFA, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 TFA shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 TFA has an additive effect on the signal transduction of galanin .
des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC50 of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC50=1.18±0.2 μM) of Nav1.5 expressed in Chinese hamster ovary (CHO-K1) cells .
des-Gln14-Ghrelin TFA is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM .
Pro8-Oxytocin is a a modified oxytocin (OXT) ligand. Pro8-Oxytocin produces more potent and efficacious responses at primate OXTR and stronger behavioral effects than the consensus mammalian OXT ligand (Leu8-Oxytocin). Pro8-Oxytocin produce a less efficacious response than Vasopressin (HY-B1811) (AVP) at human AVPR1a and higher efficacious response than AVP at marmoset AVPR1a .
LPLRF-NH2 is a member of RFamide peptide with anorexigenic effect. LPLRF-NH2 increases arterial blood pressure and modulates the electrical activity of brainstem neurons .
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .
[D-Trp8]-γ-MSH is a potent and selective agonist of melanocortin 3 (MC3) receptor, with IC50s of 6.7 nM, 600 nM and 340 nM for hMC3, hMC4 and hMC5, respectively in CHOcells. [D-Trp8]-γ-MSH could provide protection against multiple inflammatory disorders such as rheumatoid arthritis and colitis .
Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHOcells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively .
[D-Trp8]-γ-MSH TFA is a potent and selective agonist of melanocortin 3 (MC3) receptor, with IC50s of 6.7 nM, 600 nM and 340 nM for hMC3, hMC4 and hMC5, respectively in CHOcells. [D-Trp8]-γ-MSH TFA could provide protection against multiple inflammatory disorders such as rheumatoid arthritis and colitis .
Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHOcells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively .
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
MCH (human, mouse, rat) is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHOcell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
MCH (human, mouse, rat) TFA is a potent peptide agonist of MCH-R and exhibits binding IC50 values of 0.3nM and 1.5 nM for MCH1R and MCH2R, respectively. MCH (human, mouse, rat) is a highly sensitive to MCH-2R in a CHOcell line and monitoring mobilization of intracellular calcium with FLIPR, exhibits functional activation EC50 values of 3.9 nM and 0.1nM for human MCH-1R and MCH-2R, respectively .
Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2?binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHOcells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .
[Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHOcells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent .
MCE PEI Transfection Reagent is designed based on 25 kDa PEI. It has high-efficiency, low-toxicity, strong-stability, and is suitable for many cell types, such as HEK-293、HEK-293T、CHO-K1、COS-1、COS-7、NIH/3T3、Sf9、HepG2 and HeLa et, even some hard-to-transfect cells. It can also be applied to large-scale recombinant protein expression and virus production.
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHOcells. Lacutamab can be used in research of cutaneous T-cell lymphoma .
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
Anti-Dysadherin Antibody is a human antibody expressed in CHOcells, targeting dysadherin. Anti-Dysadherin Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells .
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
Efavaleukin alfa (AMG592) is a human monoclonal antibody. Efavaleukin alfa is composed of the IGHG1 Fc fragment fused to IL-2. The expression system of Efavaleukin alfa is usually CHO (Chinese Hamster Ovary) cells .
Anti-MUC17 Antibody is a human antibody expressed in CHOcells, targeting MUC17. Anti-MUC17 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHOcells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHOcells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
Anti-Clathrin Heavy Chain Antibody is a human antibody expressed in CHOcells, targeting Clathrin Heavy Chain. Anti-Clathrin Heavy Chain Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TrkB/NTRK2 Antibody is a human antibody expressed in CHOcells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-EMMPRIN/CD147 Antibody is a human antibody expressed in CHOcells, targeting Basigin. Anti-EMMPRIN/CD147 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Spike-RBD mAb is a CHOcell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
Anti-IL-25 Antibody is a human antibody expressed in CHOcells, targeting IL-25. Anti-IL-25 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHOcells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHOcell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin TSLP. The expression system of Ecleralimab is usually CHO (Chinese Hamster Ovary) cells .
Anti-EFNA4 Antibody (PF-06647263 antibody) is a human antibody expressed in CHOcells, targeting EFNA4. Anti-EFNA4 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHOcells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
CM-24 is a humanized antibody expressed in CHOcells, targeting CEACAM1/CD66a. The predicted molecular weight (MW) of CM-24 is 145 kDa. The isotype control for CM-24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
FR104 is a humanized antibody expressed in CHOcells that targets CD28. FR104 comprises a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for FR104 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) is a human antibody expressed in CHOcells, targeting CDH6. Anti-CDH6/K-Cadherin Antibody (HKT288 antibody) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-oxLDL Antibody is a humanized antibody expressed in CHOcells that targets oxLDL. The Anti-oxLDL Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-oxLDL Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CDH17/Cadherin-17 Antibody (10C12) is a human antibody expressed in CHOcells, targeting CDH17. Anti-CDH17/Cadherin-17 Antibody (10C12) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Haptoglobin Antibody is a humanized antibody expressed in CHOcells that targets Haptoglobin. The Anti-Haptoglobin Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Haptoglobin Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-HGFA Antibody is a humanized antibody expressed in CHOcells, targeting HGFA. The Anti-HGFA Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-HGFA Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Senlizumab is a humanized antibody expressed in CHOcells that targets TNFSF2/TNFa. Senlizumab is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for Senlizumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
VGX-100 is a humanized antibody expressed in CHOcells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MB-311 is a humanized antibody expressed in CHOcells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TPBG Antibody is a humanized antibody expressed in CHOcells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
Anti-LAP Antibody is a humanized antibody expressed in CHOcells, targeting LAP. The Anti-LAP Antibody features a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-LAP Antibody, you can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-vWF Antibody is a humanized antibody expressed in CHOcells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
Anti-TSLP Antibody is a human-derived antibody expressed in CHOcells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
KRN-330 is a humanized antibody expressed in CHOcells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLEC7A Antibody is a humanized antibody expressed in CHOcells, targeting CLEC7A. The predicted molecular weight (MW) of Anti-CLEC7A Antibody is 150 kDa. The isotype control for Anti-CLEC7A Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-MICB Antibody is a humanized antibody expressed in CHOcells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
SAIT-301 is a humanized antibody expressed in CHOcells, targeting HGFR/c-Met. SAIT-301 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for SAIT-301 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MVT-5873 is a humanized antibody expressed in CHOcells, targeting Sialyl-Lewis A. MVT-5873 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for MVT-5873 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
ATN-658 is a humanized antibody expressed in CHOcells that targets PLAUR/uPAR/CD87. ATN-658 contains muIgG1 heavy chain and mκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for ATN-658 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
VLST-002 is a humanized antibody expressed in CHOcells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
PY159 is a humanized antibody expressed in CHOcells, targeting TREM1/CD354. PY159 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for PY159 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
BT-063 is a humanized antibody expressed in CHOcells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
IMA-026 is a humanized antibody expressed in CHOcells that targets IL-13. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
NI-0701 is a humanized antibody expressed in CHOcells that targets CCL5/RANTES. NI-0701 has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0701 can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
R707 is a human antibody expressed in CHOcells that targets CCR7/CD197. R707 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.36 kDa. The isotype control for R707 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
STX-100 is a humanized antibody expressed in CHOcells, targeting Integrin aVb6 (ITGAV & ITGB6). STX-100 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.12 kDa. The isotype control for STX-100 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
HuGAL-F2 is a human-derived antibody expressed in CHOcells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
VB1-050 is a human antibody expressed in CHOcells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
DEDN6526A (RG-7636) is a humanized antibody expressed in CHOcells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-PAR2 Antibody is a human-derived antibody expressed in CHOcells, targeting PAR2. The Anti-PAR2 Antibody contains a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-PAR2 Antibody can be referred to as Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHOcells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CD19 Antibody is a humanized antibody expressed in CHOcells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-STOP1 Antibody is a human antibody expressed in CHOcells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
TTX-030 is a humanized antibody expressed in CHOcells, targeting ENTPD1/CD39. TTX-030 contains huIgG4SP heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for TTX-030 can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CXCL9 Antibody is a humanized antibody expressed in CHOcells, targeting CXCL9. The Anti-CXCL9 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXCL9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-GAD65 Antibody is a humanized antibody expressed in CHOcells that targets GAD65. The Anti-GAD65 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.48 kDa. The isotype control for Anti-GAD65 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TSPAN8 Antibody is a human source antibody expressed in CHOcells, targeting TSPAN8. The Anti-TSPAN8 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TSPAN8 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Orai1 Antibody is a humanized antibody expressed in CHOcells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
The Anti-IFNAR1 Antibody is a humanized antibody expressed in CHOcells, targeting IFNAR1. The Anti-IFNAR1 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.92 kDa. The isotype control for the Anti-IFNAR1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-2045 is a humanized antibody expressed in CHOcells that targets IL-4Ra/CD124. MEDI-2045 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MEDI-2045 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
VIB-9600 is a humanized antibody expressed in CHOcells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TGFb1 Antibody is a humanized antibody expressed in CHOcells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CLEC14A Antibody is a humanized antibody expressed in CHOcells, targeting CLEC14A. The Anti-CLEC14A Antibody contains an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-CLEC14A Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
MEDI-3617 is a humanized antibody expressed in CHOcells, targeting Ang2/ANGPT2/Angiopoietin2. MEDI-3617 has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for MEDI-3617 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
NEO-201 is a humanized antibody expressed in CHOcells that targets CEACAM6/CD66c. NEO-201 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.48 kDa. The isotype control for NEO-201 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-PACAP38 Antibody is a human antibody expressed in CHOcells, targeting PACAP38. The Anti-PACAP38 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PACAP38 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-Bcl-2 Antibody is a humanized antibody expressed in CHOcells, targeting Bcl-2. The Anti-Bcl-2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Bcl-2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
RG-7212 (RO5458640) is a human-derived antibody expressed in CHOcells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
OS-2966 is a humanized antibody expressed in CHOcells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
LIV-1205 (CBA-1205) is a humanized antibody expressed in CHOcells that targets DLK1. LIV-1205 (CBA-1205) contains a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LIV-1205 (CBA-1205) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHOcells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHOcells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
IMC-C103C is a human antibody expressed in CHOcells, targeting MAGE-A4. IMC-C103C contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for IMC-C103C can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DSG3 Antibody is a humanized antibody expressed in CHOcells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
AMG-108 is a humanized antibody expressed in CHOcells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
ABX-IL8 is a human-derived antibody expressed in CHOcells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHOcells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CLDN6 Antibody (DS-9606A antibody) is a humanized antibody expressed in CHOcells, targeting CLDN6. Anti-CLDN6 Antibody features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for Anti-CLDN6 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-FOLR1/FRA Antibody is a humanized antibody expressed in CHOcells, targeting FOLR1/FRA. The Anti-FOLR1/FRA Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.46 kDa. The isotype control for the Anti-FOLR1/FRA Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-Melanotransferrin/CD228 Antibody (SC-005 antibody) is a humanized antibody expressed in CHOcells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-ACVR2B Antibody is a human antibody expressed in CHOcells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ADAM9 Antibody (MGA021) (IMGC-936 antibody) is a humanized antibody expressed in CHOcells that targets ADAM9. Anti-ADAM9 Antibody (MGA021) is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 147.62 kDa. The isotype control for Anti-ADAM9 Antibody (MGA021) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHOcells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is a humanized antibody expressed in CHOcells, targeting EphA2. Anti-EphA2 Antibody (1C1) contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for Anti-EphA2 Antibody (1C1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-FGFR1/CD331 Antibody is a humanized antibody expressed in CHOcells, targeting FGFR1/CD331. The Anti-FGFR1/CD331 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FGFR1/CD331 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-TNFSF2/TNFa Antibody (hMAK195) is a human antibody expressed in CHOcells that targets TNFSF2/TNFa. Anti-TNFSF2/TNFa Antibody (hMAK195) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.06 kDa. The isotype control for Anti-TNFSF2/TNFa Antibody (hMAK195) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHOcells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Osemitamab (FUT8-KO) is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study. Osemitamab (FUT8-KO) antibody is expressed in FUT8-knockout CHOcells. Osemitamab (FUT8-KO) possesses a more potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) than Osemitamab .
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHOcells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
Anti-CEACAM1/CD66a Antibody is a human antibody expressed in CHOcells that targets CEACAM1/CD66a. The Anti-CEACAM1/CD66a Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.98 kDa. The isotype control for the Anti-CEACAM1/CD66a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHOcells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-TEM7R/PLXDC2 Antibody is a human-derived antibody expressed in CHOcells, targeting TEM7R/PLXDC2. The Anti-TEM7R/PLXDC2 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-TEM7R/PLXDC2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-MSPR/RON/CD136 Antibody (H5B14) is a humanized antibody expressed in CHOcells, targeting MSPR/RON/CD136. Anti-MSPR/RON/CD136 Antibody (H5B14) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. The isotype control for Anti-MSPR/RON/CD136 Antibody (H5B14) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CTLA-4/CD152 Antibody is a humanized antibody expressed in CHOcells that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-Siglec-15/CD33L3 Antibody is a human-derived antibody expressed in CHOcells, targeting Siglec-15/CD33L3. The Anti-Siglec-15/CD33L3 Antibody contains a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for the Anti-Siglec-15/CD33L3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHOcells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
The Anti-LY75/CD205 Antibody (MEN1309) is a human antibody expressed in CHOcells, targeting LY75/CD205/DEC-205. The Anti-LY75/CD205 Antibody (MEN1309) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.36 kDa. For the isotype control of Anti-LY75/CD205 Antibody (MEN1309), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .
The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) is a humanized antibody expressed in CHOcells, targeting CDH17/Cadherin-17. The Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) features an IgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 149.12 kDa. The isotype control for the Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-ENPP3/CD203c Antibody (AGS-16C3F antibody) is a humanized antibody expressed in CHOcells, targeting ENPP3/CD203c. Anti-ENPP3/CD203c Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 154.04 kDa. The isotype control for Anti-ENPP3/CD203c Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) is a humanized antibody expressed in CHOcells, targeting AA2AR/Adenosine A2aR. Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.66 kDa. The isotype control for Anti-AA2AR/Adenosine A2aR Antibody (3F6-9G5) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC50 value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .
Hyodeoxycholic acid (Standard) is the analytical standard of Hyodeoxycholic acid. This product is intended for research and analytical applications. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
Hyodeoxycholic acid (Standard) is the analytical standard of Hyodeoxycholic acid. This product is intended for research and analytical applications. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
Leoidin is an OATP1B1 and OATP1B3 inhibitor with Ki values of 0.08 and 1.84 µM, respectively. Leoidin inhibits sodium fluorescein uptake in CHOcells expressing the human OATP1B1 and OATP1B3. Leoidin is an antibacterial agent against both Gram-positive and Gram-negative pathogens. Leoidin inhibits phenylalanyl-tRNA synthetase (PheRS) (IC50= 42 µM) and inhibits protein synthesis in bacterial. Leoidin can be isolated from L. gangaleoides .
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
IL-7 Protein, Mouse (CHO) is constitutively produced by stromal cells from the bone marrow and thymus, plays a crucial role in B cell lymphopoiesis and in T cell homeostasis.
IL-3 Protein, Human (CHO) is a multilineage hematopoietic cytokine with promising effects on platelet and neutrophil counts and special usefulness in patients with secondary hematopoietic failure.
IL-9 Protein, Mouse (CHO), derived from CHO cell, is a member of the TH2 cytokine family.IL-9 Protein, Mouse (CHO) has recently been implicated as an essential factor in determining mucosal immunity and susceptibility to atopic asthma.
CD19 Protein, Human (CHO, Fc) is a polypeptide chain with the C-terminal human IgG1 Fc fragment produced in CHO cells. CD19 is a biomarker for normal and neoplastic B cells.
The NKG2D/CD314 protein serves as a key activating and costimulatory receptor in immune surveillance, binding to multiple stress-inducing ligands on tumor and virus-infected cells. It plays a dual role by stimulating NK cells and enhancing T cell activation in CD8(+) T cell-mediated adaptive responses. NKG2D/CD314 Protein, Human (CHO, Fc) is the recombinant human-derived NKG2D/CD314 protein, expressed by CHO , with N-hFc labeled tag. The total length of NKG2D/CD314 Protein, Human (CHO, Fc) is 139 a.a., with molecular weight of 50-64 & 37 KDa, respectively.
KIR3DS1/CD158e2, located on NK cells, serves as a receptor for MHC class I molecules. Its crucial role includes triggering NK cell degranulation and inducing the production of anti-viral cytokines upon interaction with the peptide-free HLA-F open conformer. This direct engagement highlights KIR3DS1/CD158e2 as a key modulator of NK cell responses, particularly in anti-viral immune reactions. KIR3DS1/CD158e2 Protein, Human (CHO) is the recombinant human-derived KIR3DS1/CD158e2 protein, expressed by CHO , with tag free. The total length of KIR3DS1/CD158e2 Protein, Human (CHO) is 319 a.a., with molecular weight of 75-90 kDa.
Indomethacin-d4 Methyl Ester is the deuterium labeled Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHOcells[1]. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes[2].
Diclofenac-d4 (sodium) is the deuterium labeled Diclofenac sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3].
Diclofenac-d4 is the deuterium labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3].
Diclofenac- 13C6 is the 13C6 labeled Diclofenac. Diclofenac is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.
Mianserin-d3 is the deuterium labeled Mianserin (HY-B0188). Mianserin? is a Histamine 1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant .
Hyodeoxycholic acid-d5 is the deuterium labeled Hyodeoxycholic acid. Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHOcells.
Indomethacin-d4 is a deuterium labeled Indomethacin. Indomethacin is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHOcells[1]. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes[2].
Aldicarb sulfoxide-d3 is the deuterium labled Aldicarb sulfoxide (HY-124104). Aldicarb sulfoxide is a metabolite of Aldicarb. Aldicarb sulfoxide affects the glutathione-linked enzymes in CHO-K1 cells. Aldicarb sulfoxide inhibits cholinesterase (ChE) and carboxylesterase (CaE) with IC50 of 10 μM for both in zebrafish .
Diclofenac- 13C6 (sodium heminonahydrate) is the 13C-labeled Diclofenac Sodium. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells[1], and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively[2]. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade[3].
Diclofenac- 13C6 (Sodium) is the 13C6 labeled Diclofenac (Sodium). Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHOcells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.
Salmeterol-d3 is a deuterium labeled Salmeterol. Salmeterol is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].
Salmeterol-d5 is a deuterated labeled Salmeterol . Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively .
Salmeterol-d3 (xinafoate) is the deuterium labeled Salmeterol xinafoate. Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].
Salmeterol- 13C6 (xinafoate) is the 13C6 labeled Salmeterol (xinafoate). Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHOcells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
![ANP [Des18-22] 4-23 amide (rat)](http://file.medchemexpress.eu/product_pic/hy-p1526.gif)
![[DPro10] Dynorphin A (1-11), porcine](http://file.medchemexpress.eu/product_pic/hy-p3647.gif)
![[D-Trp8]-γ-MSH](http://file.medchemexpress.eu/product_pic/hy-p1217.gif)
![[D-Trp8]-γ-MSH TFA](http://file.medchemexpress.eu/product_pic/hy-p1217a.gif)
![[Nphe1]Nociceptin(1-13)NH2 TFA](http://file.medchemexpress.eu/product_pic/hy-p1320a.gif)
![[Nphe1]Nociceptin(1-13)NH2](http://file.medchemexpress.eu/product_pic/hy-p1320.gif)
